Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Unicycive Therapeutics Inc
(NQ:
UNCY
)
0.3090
+0.0090 (+3.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Unicycive Therapeutics Inc
< Previous
1
2
Next >
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
September 06, 2023
Appointment adds decades of drug development experience from a seasoned executive
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
August 29, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive: The Company Developing Key Kidney Therapies
February 17, 2023
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.
Via
TheNewswire.com
CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
July 21, 2023
Via
ACCESSWIRE
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
July 21, 2023
Via
ACCESSWIRE
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 18, 2023
Newly Assigned USAN Name, Oxylanthanum Carbonate, replaces Lanthanum Dioxycarbonate
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
June 29, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 16, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®
June 09, 2023
Via
ACCESSWIRE
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
May 16, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
April 24, 2023
Data highlights the potential safety and reno-protective effect of UNI-494
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
March 31, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug
March 08, 2023
Via
Investor Brand Network
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
March 07, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 06, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
March 03, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 27, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 02, 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 23, 2023
Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 05, 2023
Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
December 29, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
December 28, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
December 22, 2022
Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
December 09, 2022
Via
ACCESSWIRE
Unicycive to Participate in Upcoming Investor Conferences
November 28, 2022
Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
November 21, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Announces Third Quarter Financial Results and Provides Business Update
November 14, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
November 10, 2022
From
Unicycive Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.